ArticleJournal of obstetrics and gynaecology of India2025
Maternal Serum Cyclophilin A: A Predictive Biomarker of Preeclampsia in South Indian Women.
Article in Journal of obstetrics and gynaecology of India, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Serum Cyclophilin A (CyPA) is a 20 KD chaperone protein, secreted in response to oxidative stress and has an important role as mediator of inflammation. CyPA has been related to Preeclampsia (PE) and implicated as its potential biomarker. Objectives: To analyze serum Cyclophilin A levels in preeclamptic women and compare it with healthy pregnant women, in South India. We aimed to look for its validity as a predictive biomarker for PE. Methods: This is a prospective cohort study, conducted in pregnant women attending the OPD of a private medical college hospital in Salem. Maternal serum CyPA levels were assessed in PE and healthy pregnant women in their 2nd trimester (20-26 weeks) and repeated again in the 3rd trimester of PE women. Results: Among 120 pregnant women recruited for the study, 60 were preeclamptic and 60 were healthy pregnant women. Higher serum CyPA levels were observed in PE group (34.58 ± 5.53 ng/ml), compared to healthy pregnant women (7.41 ± 7.7 ng/ml), Conclusion: CyPA levels were markedly increased in preeclampsia, and could be a novel biomarker of preeclampsia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.